Literature DB >> 11378678

Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer.

F M Silva1, S Zaterka, J N Eisig, E Z Chehter, D Chinzon, A A Laudanna.   

Abstract

UNLABELLED: Triple therapy is accepted as the treatment of choice for H. pylori eradication. In industrialized countries, a proton pump inhibitor plus clarithromycin and amoxicillin or nitroimidazole have shown the best results. Our aims were: 1. To study the eradication rate of the association of a proton pump inhibitor plus tinidazole and clarithromycin on H. pylori infection in our population. 2. To determine if previous treatments, gender, age, tobacco, alcohol use, and non-steroidal anti-inflammatory drugs (NSAIDs) change the response to therapy.
METHODS: Two hundred patients with peptic ulcer (upper endoscopy) and H. pylori infection (histology and rapid urease test - RUT) were included. A proton pump inhibitor (lanzoprazole 30 mg or omeprazole 20 mg), tinidazole 500 mg, and clarithromycin 250 mg were dispensed twice a day for a seven-day period. Eradication was assessed after 10 to 12 weeks of treatment through histology and RUT.
RESULTS: The eradication rate of H. pylori per protocol was 65% (128/196 patients). This rate was 53% for previously treated patients, rising to 76% for not previously treated patients, with a statistical difference p<0.01. No significant difference was observed regarding sex, tobacco use, alcohol consumption, and NSAID use, but for elderly patients the difference was p = 0.05. Adherence to treatment was good, and side effects were mild.
CONCLUSIONS: A proton pump inhibitor, tinidazole, and clarithromycin bid for seven days resulted in H. pylori eradication in 65% of the patients. Previous treatments were the main cause of treatment failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378678     DOI: 10.1590/s0041-87812001000100003

Source DB:  PubMed          Journal:  Rev Hosp Clin Fac Med Sao Paulo        ISSN: 0041-8781


  7 in total

1.  The impact of oral ciprofloxacin on the structure and functions of rat gastric mucosa.

Authors:  Nihal A Ibrahim; Kadreya E Elmorshedy; Doaa A Radwan; Manal A Buabeid
Journal:  Saudi J Biol Sci       Date:  2021-11-24       Impact factor: 4.052

2.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

3.  Levofloxacin-containing versus Clarithromycin-containing Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial.

Authors:  Vahid Sebghatollahi; Maryam Soheilipour; Mahsa Khodadoostan; Alireza Shavakhi; Ahmad Shavakhi
Journal:  Adv Biomed Res       Date:  2018-03-27

4.  Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.

Authors:  Jaime N Eisig; Fernando M Silva; Ricardo C Barbuti; Tomás Navarro Rodriguez; Peter Malfertheiner; Joaquim P P Moraes Filho; Schlioma Zaterka
Journal:  BMC Gastroenterol       Date:  2009-05-26       Impact factor: 3.067

5.  Short-term triple therapy with azithromycin for Helicobacter pylori eradication: low cost, high compliance, but low efficacy.

Authors:  Fernando M Silva; Jaime N Eisig; Ana Cristina S Teixeira; Ricardo C Barbuti; Tomás Navarro-Rodriguez; Rejane Mattar
Journal:  BMC Gastroenterol       Date:  2008-05-29       Impact factor: 3.067

6.  Eradication Rate of Helicobacter pylori using a Two-week Quadruple Therapy: A Report from Southern Iran.

Authors:  Mohsen Masoodi; Mohammad Panahian; Amirmansoor Rezadoost; Amin Heidari
Journal:  Middle East J Dig Dis       Date:  2013-04

7.  Self-reported adverse drug effects and associated factors among H. pylori infected patients on standard triple therapy: Prospective follow up study.

Authors:  Endalew Gebeyehu; Desalegn Nigatu; Ephrem Engidawork
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.